The neutralizing efficacy of 6F6 was assessed in vitro using colony formation assays involving multiple CLDN1 overexpressing cancer models (pancreatic: BXPC3, PANC-1; ovarian: SKOV-3, IGROV1; hepatocellular: HuH-7) as well as a xenograft model of CRC. The gene discussed is CLDN1; the disease is colorectal carcinoma.